Generic Name and Formulations:
Dexamethasone 0.7mg in the Novadur delivery system; intravitreal implant; preservative-free.
Indications for OZURDEX:
Macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Non-infectious uveitis affecting the posterior segment of the eye. Diabetic macular edema.
For ophthalmic intravitreal injection only. One implant in each affected eye(s).
Ocular or periocular infections. Glaucoma (cup to disc ratio >0.8). Torn or ruptured posterior lens capsule.
Monitor for intravitreal injection-related effects (eg, endophthalmitis, eye inflammation, increased intraocular pressure, retinal detachments) following the injection. Risk of potential steroid-related effects (eg, posterior subcapsular cataracts, glaucoma, secondary ocular infections). History of ocular herpes simplex: not recommended. Risk of implant migration to anterior chamber if posterior lens capsule is not intact. Pregnancy. Nursing mothers.
Increased intraocular pressure, conjunctival hemorrhage, eye pain, conjunctival hyperemia, ocular hypertension, cataracts.
Single-use intravitreal implant—1 (w. applicator)
Renal and Urology News Articles
- Novel Albuminuria Endpoints May Improve CKD Progression Trials
- Comorbidities Adversely Linked to Cancer Trial Participation
- Global Demand for Bladder Cancer Treatment Threatens Supply in 2019
- Opioids Now More Deadly for Americans Than Traffic Accidents
- New Predictor of In-Hospital Acute Kidney Injury Identified
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)